Chronic lymphocytic leukaemia is the most common leukaemia subtype and associated with profound immunosuppression. Bruton Tyrosine Kinase inhibitors have revolutionised chronic lymphocytic leukaemia management; however, Bruton Tyrosine Kinase inhibitors therapy impairs vaccine-induced immunity. We evaluated if a 3-week pause of Bruton Tyrosine Kinase inhibitors treatment improved spike protein receptor binding domain immunity to severe acute respiratory syndrome coronavirus 2 vaccination while maintaining disease control.
